Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota – The "RISTOMED project": Randomized controlled trial in healthy older people. Issue 4 (August 2015)

• Record Type: Journal Article
• Authors: Valentini, Luzia; Pinto, Alessandro; Bourdel-Marchasson, Isabelle; Ostan, Rita; Brigidi, Patrizia; Turroni, Silvia; Hrelia, Silvana; Hrelia, Patrizia; Bereswill, Stefan; Fischer, André; Leoncini, Emanuela; Malaguti, Marco; Blanc-Bisson, Christéle; Durrieu, Jessica; Spazzafumo, Liana; Buccolini, Fabio; Pryen, Florence; Donini, Lorenzo Maria; Franceschi, Claudio; Lochs, Herbert
• Is Part Of: Clinical nutrition. Volume 34:Issue 4(2015:Aug.)
• Page Start: 593
• Page End: 602
• Publication Date: 2015-08
• Subjects: Critically ill -- Nutrition -- Periodicals; Diet therapy -- Periodicals; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; Enteral Nutrition -- Periodicals; Parenteral Nutrition -- Periodicals; Metabolism -- Periodicals; Diétothérapie -- Périodiques; Alimentation parentérale -- Périodiques; Alimentation entérale -- Périodiques; Nutrition -- Périodiques; Diet therapy; Enteral feeding; Nutrition; Parenteral feeding; Electronic journals; Periodicals; Electronic journals; 615.854
• DOI: 10.1016/j.clnu.2014.09.023
• Languages: English
• ISSNs: 0261-5614

Abstract

<abstract xml:lang="en" abstract-type="author" id="abs0010"> <title id="sectitle0010">Summary</title> <sec> <title id="sectitle0015">Objectives</title> <p id="abspara0010">To assess the impact of a personalized diet, with or without addition of VSL#3 preparation, on biomarkers of inflammation, nutrition, oxidative stress and intestinal microbiota in 62 healthy persons aged 65–85 years.</p> </sec> <sec> <title id="sectitle0020">Design</title> <p id="abspara0015">Open label, randomized, multicenter study. Primary endpoint: High-sensitivity C-reactive protein.</p> </sec> <sec> <title id="sectitle0025">Setting</title> <p id="abspara0020">Community.</p> </sec> <sec> <title id="sectitle0030">Interventions</title> <p id="abspara0025">Eight week web-based dietary advice (RISTOMED platform) alone or with supplementation of VSL#3 (2 capsules per day). The RISTOMED diet was optimized to reduce inflammation and oxidative stress.</p> </sec> <sec> <title id="sectitle0035">Measurements</title> <p id="abspara0030">Blood and stool samples were collected on days 1 and 56.</p> </sec> <sec> <title id="sectitle0040">Results</title> <p id="abspara0035">Diet alone reduced ESR (<italic>p</italic> = 0.02), plasma levels of cholesterol (<italic>p</italic> < 0.01) and glucose (<italic>p</italic> = 0.03). Addition of VSL#3 reduced ESR (<italic>p</italic> = 0.05) and improved folate (<italic>p</italic> = 0.007), vitamin B12 (<italic>p</italic> = 0.001) and homocysteine (<italic>p</italic> < 0.001) plasma levels. Neither intervention demonstrated any further effects on inflammation. Subgroup analysis showed 40 participants without signs of low-grade inflammation (hsCRP<3 mg/l, subgroup 1) and 21 participants with low-grade inflammation at baseline (hsCRP≥3 mg/l, subgroup 2). In subgroup 2 addition of VSL#3 increased bifidobacteria (<italic>p</italic> = 0.005) in more participants and improved both folate (<italic>p</italic> = 0.015) and vitamin B12 (<italic>p</italic> = 0.035) levels compared with subgroup 1. The increases were positively correlated to the change in the bifidobacteria concentration for folate (<italic>p</italic> = 0.023) and vitamin B12 (<italic>p</italic> = 0.001). As expected change in homocysteine correlated negatively to change in folate (<italic>r</italic> = −0.629, <italic>p</italic> = 0.002) and vitamin B12 (<italic>r</italic> = −0.482, <italic>p</italic> = 0.026).</p> </sec> <sec> <title id="sectitle0045">Conclusions</title> <p id="abspara0040">Addition of VSL#3 increased bifidobacteria and supported adequate folate and vitamin B12 concentrations in subjects with low-grade inflammation. Decrease in homocysteine with VSL#3 was clinically relevant. suggesting protective potentials for aging-associated conditions, e.g. cardiovascular or neurological diseases.</p> <p id="abspara0045"> <ext-link ext-link-type="unknown" id="intref0010" xlink:type="simple" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>: <ext-link ext-link-type="unknown" id="intref0015" xlink:type="simple" xlink:href="ctgov:NCT01069445" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01069445</ext-link>–<ext-link ext-link-type="unknown" id="intref0020" xlink:type="simple" xlink:href="ctgov:NCT01179789" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01179789</ext-link>.</p> </sec> </abstract>